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Chemokine (C–C motif) ligand 2 (CCL2) has been associated with chronic metabolic diseases. We aimed 
to investigate whether Ccl2 gene overexpression is involved in the regulation of signaling pathways 
in metabolic organs. Biochemical and histological analyses were used to explore tissue damage in 
cisgenic mice that overexpressed the Ccl2 gene. Metabolites from energy and one‑carbon metabolism 
in liver and muscle extracts were measured by targeted metabolomics. Western blot analysis was used 
to explore the AMP‑activated protein kinase (AMPK) and mammalian target of rapamycin pathways. 
Ccl2 overexpression resulted in steatosis, decreased AMPK activity and altered mitochondrial 
dynamics in the liver. These changes were associated with decreased oxidative phosphorylation 
and alterations in the citric acid cycle and transmethylation. In contrast, AMPK activity and its 
downstream mediators were increased in muscle, where we observed an increase in oxidative 
phosphorylation and increased concentrations of different metabolites associated with ATP synthesis. 
In conclusion, Ccl2 overexpression induces distinct metabolic alterations in the liver and muscle that 
affect mitochondrial dynamics and the regulation of energy sensors involved in cell homeostasis. 
These data suggest that CCL2 may be a therapeutic target in metabolic diseases.
Research on the factors that relate the immune system to metabolic alterations in chronic diseases is clini-
cally important because it can allow the identification of therapeutic targets. It remains unclear how immunity 
affects systemic metabolism, but experimental evidence supports an intertwined relationship through interorgan 
metabolic crosstalk and mitochondrial  dynamics1–3. One of the consequences of these processes is metabolic 
stress leading to adaptive responses and altered cellular  communication4. Autophagy, a lysosomal degradation 
pathway, appears to be the most important effector in the adaptation to metabolic stress and removal of damaged 
organelles. Among the molecular sensors that modulate autophagy, the AMP-activated protein kinase (AMPK) 
and mammalian target of rapamycin (mTOR)-driven pathways play a crucial role in mitochondrial dysfunction 
and favor a bidirectional relationship between metabolism and  inflammation4,5.
Chemokines, especially chemokine (C–C motif) ligand 2 (CCL2), have various functions that are involved in 
the maintenance of normal metabolism. CCL2 participates, directly and/or through the induced metabolic altera-
tions, in the regulation of mitochondrial biogenesis and  autophagy6,7. This chemokine also affects immune and 
inflammatory reactions and may compromise cell homeostasis and energy requirements in metabolic  organs8,9. 
Growing evidence indicates that in both humans and experimental animals, the Ccl2 gene is overexpressed 
in noncommunicable diseases characterized by a low degree of systemic inflammation and various metabolic 
 alterations10–14. Recently, the relationships among mitochondrial dysfunction, autophagy and chronic diseases 
open
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have been linked to  CCL215. Therefore, we hypothesized that CCL2 overexpression may actively contribute to 
the energy-related adaptive responses of metabolic organs through the regulation of intracellular sensors and 
signaling molecules. We then assessed the putative role of Ccl2 in energy metabolism and one-carbon metabolism 
in cisgenic mice that systemically overexpress Ccl2 (CgCcl2). Our results showed that the effects of Ccl2 over-
expression diverge in muscle and liver metabolism by inducing opposite alterations in energy and one-carbon 
metabolism, mitochondrial function and autophagy-related pathways.
Results
Variations in metabolic phenotype were associated with Ccl2 overexpression. All animals were 
matched for age. The CgCcl2 mice did not show any significant differences in terms of frailty, behavior, repro-
duction or food intake compared to the wild-type (WT) mice. The body weight of these mice was lower than 
that of the WT mice, and there were significant alterations in the concentrations of serum glucose, cholesterol 
and triglycerides. The serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities 
of the CgCcl2 mice were higher than those of WT mice (Fig. 1). As expected, the CgCcl2 mice had higher CCL2 
concentrations than the WT mice in all tissues examined, and Ccl2 overexpression was associated with higher 
relative liver weight and lower relative muscle weight (Fig. 2). Histological analysis revealed that the CgCcl2 
mice accumulated lipid droplets in the liver and had muscle atrophy without major differences in other tissues. 
The liver and muscle tissues did not have any evidence of fibrosis and had fewer F4/80-stained cells (a marker 
of macrophages) than those of the WT animals (Fig. 3A). In the liver, the CgCcl2 mice had lower expression of 
proinflammatory markers such as cluster of differentiation (CD) 11b and tumor necrosis factor-alpha (TNFα) 
and higher expression of CD163, which is an anti-inflammatory marker, than the WT mice. In muscular tissue, 
we found a significant decrease only in TNFα expression, but the levels of CD11b and CD163 in the CgCcl2 mice 
were similar to those found in WT animals (Fig. 3B). Analysis of the expression of these genes by quantitative 
real-time polymerase chain reaction (qPCR) gave similar results (Supplementary Fig. S1).
Ccl2 overexpression induced opposite changes in mitochondrial quality and function in the 
liver and muscle. To investigate whether Ccl2 overexpression was associated with mitochondrial altera-
tions, we assessed the expression of mitochondrial electron transport chain (ETC) complex proteins, as well as 
the mitochondrial import receptor subunit translocase of outer membrane 20 (TOM20), which is responsible for 
the recognition and translocation of cytosolically synthesized mitochondrial preproteins; mitofusin 2 (MFN2), 
which is required for mitochondrial fusion; and PTEN-induced putative kinase 1 (PINK1)/E3 ubiquitin- pro-
tein ligase parkin (PARKIN), two molecules involved in degradation of depolarized mitochondria. The CgCcl2 
mice had decreased levels of the oxidative phosphorylation complexes I (CI-NDUFB8), III (CIII-UQCRC2), IV 
(MTCO1), and V (CVNDUFB8) but not complex II (CII-SDHB); downregulation of MFN2 and upregulation of 
PINK1 without changes in PARKIN in the liver (Fig. 4A,B). PINK1 contributes to the identification of depolar-
ized mitochondria, and PARKIN induces the degradation of damaged mitochondria by autophagolysosomes. 
In addition, the CgCcl2 mice had an increase in hepatic mitochondrial density (a reflection of the number of 
mitochondria), which is consistent with the increase in TOM20 expression. The mitochondrial matrix was con-
Figure 1.  Selected metabolic features in the wild-type (WT) and Ccl2 cisgenic mice (CgCcl2). The results are 
shown for (A) body weight increase and (B) biochemical variables and are shown as the mean ± SEM (n = 8 for 
each group). *P < 0.05; **P < 0.001, with respect to the WT control littermates.
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sistently less electrodense and the mitochondria were less interconnected and smaller than those in the WT mice 
(Supplementary Fig. S2). Therefore, our data suggest that the CgCcl2 mice had a high number of mitochondria 
in the liver due to an inhibition of mitochondrial degradation. The hepatic concentration of ATP was increased 
(Fig. 4C). Conversely, Ccl2 overexpression in the muscle resulted in enhanced levels of complexes I, II, IV, and V 
of the ETC and a decrease in TOM20 expression without any significant alterations in MFN2, PINK1 and ATP 
(Fig. 4).
Ccl2 overexpression induced different alterations in metabolites from energy and one‑carbon 
metabolism in the liver and muscle. To explore pathways of energy adaptation in the mice with Ccl2 
overexpression compared to the controls, we used a targeted metabolomic approach to examine the metabolites 
from energy and one-carbon metabolism in the liver and muscle extracts (Supplementary Tables S1 and S2). 
There were differences between tissues and strains. In the liver, oxidative metabolism was relatively reduced 
in the CgCcl2 mice with lower concentrations of citrate, oxaloacetate and fumarate, isolated accumulation of 
glucose-6-phosphate and probable alterations in the monophosphate shunt, likely indicating low replenishment 
of the citric acid cycle (CAC). Interestingly, liver succinate was increased without changes in amino acid metabo-
lism, which suggests alterations in mitochondrial function. Partial least squares discriminant analysis (PLS-DA) 
and random forest analyses revealed major differences between the strains and showed that metabolites from 
CAC distinguished the mice with and without Ccl2 overexpression (Fig. 5A). In contrast, in the muscle extracts, 
pyruvate provided the highest variable of importance score, denoting the relative accumulation of glucose, 
3-phosphoglycerate, pyruvate, lactate, ribose 5-phosphate and β-hydroxybutyrate. Thus, anaplerosis-associated 
pathways were increased in the muscles of the CgCcl2 mice compared to the WT mice, which correlated with 
the relative accumulation of metabolites from CAC, especially succinate, aconitate and oxaloacetate (Fig. 5B).
PLS-DA and random forest analyses also revealed that metabolites from one-carbon metabolism segregated 
the strains according to Ccl2 overexpression and highlighted major differences in the tissue-specific metabolic 
adaptations (Fig. 6). In the liver, alterations induced by Ccl2 overexpression were consistent and mostly related 
to homocysteine transmethylation. Specifically, the depletion of methionine and the relative accumulation of 
choline, dimethylglycine, betaine, and 5-methyltetrahydrofolate strongly suggested an acquired dysfunction in 
betaine homocysteine methyltransferase (Fig. 6A). In contrast, one-carbon metabolism was not significantly 
altered in the muscle tissue (Fig. 6B).
Figure 2.  Increased Ccl2 levels in the metabolic tissues from the Ccl2 cisgenic mice (CgCcl2). The results are 
shown for (A) the Ccl2 concentrations in the liver, white adipose tissue (eWAT), pancreas, muscle and brown 
adipose tissue (BAT) of the wild-type (WT) and CgCcl2 mice and (B) the relative weight of the selected tissues. 




Scientific RepoRtS |        (2020) 10:11954  | https://doi.org/10.1038/s41598-020-68769-7
www.nature.com/scientificreports/
Figure 3.  CCL2 overexpression induces histological alterations in the liver and muscle. (A) Representative 
microphotographs of the liver and muscle sections stained with hematoxylin and eosin (H&E), Sirius red and 
F4/80 marker. (B) Western blot analyses of clusters of differentiation (CD) 11b, tumor necrosis factor (TNFα), 
and CD163. Arrowheads indicate hepatic steatosis, and arrows show positive staining for Sirius red (collagen 
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Figure 4.  CCL2 affects the mitochondrial function. (A) Schematic representation of the oxidative 
phosphorylation complexes (OXPHOS). (B) Effects of CCL2 overexpression on OXPHOS, translocase of the 
outer membrane (TOM20), mitofusin 2 (MFN2), PTEN-induced kinase 1 (PINK1) and PARKIN. (C) ATP 
concentrations. The results are shown as the mean ± SEM. *P < 0.05 with respect to the WT control littermates.
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Ccl2 overexpression induced tissue‑specific responses in autophagy‑related path‑
ways. Autophagy participates in the elimination of damaged mitochondria, has strong anti-inflammatory 
effects and improves energy homeostasis. Increased CCL2 levels were shown to influence autophagy-mediated 
cell fate decisions activating mTORC1 through simultaneous regulation of both the AMPK and protein kinase B 
(AKT)  pathways15. Therefore, we explored the potential impact of Ccl2 overexpression in the liver and muscle on 
these metabolic sensors. In the liver, Ccl2 overexpression decreased AMPK activity and upregulated mTORC1 
Figure 5.  Effects of CCL2 overexpression on the levels of metabolites associated with energy metabolism. The 
results are shown for the liver (A) and muscle extracts (B) and include the partial least square discriminant 
analysis (PLS-DA), as well as random forest analysis and quantitative comparisons between the Ccl2 cisgenic 
mice and the control littermates.
Figure 6.  Effects of CCL2 overexpression on the levels of metabolites associated with one-carbon metabolism. 
The results are shown for the liver (A) and muscle extracts (B), and discrimination between strains was assessed 
via partial least square discriminant and random forest analyses.
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compared to those in the WT mice, as indicated by the lower AMPK phosphorylation and higher ribosomal 
protein S6 phosphorylation, respectively. The decrease in the ratio between forms II and I of the microtubule-
associated protein 1A/1B light chain 3B (LC3II/LC3I ratio) and the reduced expression of sequestosome 1 (p62/
SQSTM1) without changes in the lysosome-associated membrane protein 2 (LAMP2A) levels strongly indicated 
decreased autophagy in the livers of the CgCcl2 mice. The reduction in autophagosome formation was con-
firmed by alterations in phosphoinositide 3-kinase (PI3K-p85) and AKT-pS473, which indicated dysfunction 
in the insulin growth factor pathway (Fig. 7A,B). In muscle from the CgCcl2 mice, autophagy was activated 
compared to that in the WT mice, in which AMPK phosphorylation and the LC3II/LC3I ratio were increased, 
although the p62/SQSTM1 levels were decreased. Notably, LAMP2A expression in the CgCcl2 mice was signifi-
cantly decreased, indicating a potential effect on chaperone-mediated autophagy without any effect on PI3K-p85 
expression or the pAKT/AKT ratio (Fig. 7B).
Discussion
Recent data have demonstrated that the biological function of Ccl2 extends far beyond the recruitment of mono-
cytes and the overall inflammatory response. Ccl2 protein and mRNA expression may be found in most cells 
and virtually all  tissues16,17, and this wide distribution suggests a coordinated role in adaptive responses to sys-
temic injuries. Ccl2 signals through G protein-coupled receptors may strongly affect metabolism and have been 
accepted as a potential link between immune and metabolic functions underlying human chronic  diseases18–23. 
High circulating levels of CCL2 correlate with biological age in mammals and are closely associated with a del-
eterious course of chronic  diseases24–27. Our findings indicated that CCL2 may be locally involved in multiple 
metabolic pathways and, more importantly, shows paracrine effects with different outcomes in important meta-
bolic  organs28. Indeed, our study showed that overexpression of CCL2 in mice is associated with increased liver 
and decreased muscle weights, which largely mimics a phenotype frequently found in some human metabolic 
Figure 7.  Effects of CCL2 on autophagy-related pathways. (A) Schematic overview and (B) overall assessment 
of expression levels measured by Western blot analysis of selected molecules. The results are shown as the 
mean ± SEM. *P < 0.05, with respect to the WT control littermates. PI3K-p85 phosphoinositide 3-kinase p85 
subunit, AKT protein kinase B, S6 ribosomal protein, S6-Ps235/236, phospho-S6 ribosomal protein, AMPK 
AMP-activated protein kinase, LC3 microtubule-associated protein 1A/1B light chain 3B, p62/SQSTM1 
sequestosome 1, LAMP2A lysosome-associated membrane protein 2, FAH fumarylacetoacetate hydrolase.
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diseases, such as obesity, chronic liver disease or metabolic syndrome, and in aging. Metabolically active CCL2 
is secreted by senescent  cells29, and Ccl2 overexpression can have positive or negative effects, depending on the 
context. In our model, the decreased expression of the F4/80 antigen in liver and muscle induced a shift towards 
decreased pro-inflammatory activity. A previous study by our group already showed that the CgCcl2 mice had 
decreased expression of the F4/80 antigen and the chemokine receptor CCR7, inducing a shift towards lower 
pro-inflammatory  activity13. The reasons for these findings are not known, but other authors reported a dual 
dose-dependent effect (pro- or anti-inflammatory) of CCL2 both in vitro and in vivo. These researchers sug-
gested that low levels of CCL2 could be anti-inflammatory, while high levels would be pro-inflammatory. This 
dual effect of CCL2 would be independent of its effects on  metabolism30,31. In mice, high Ccl2 expression for 
a protracted period of time increases the expression of anti-inflammatory genes in metabolic tissues and may 
reduce the inflammatory response, but this effect may differ among  organs32.
This anti-inflammatory response did not counteract the observed metabolic damage in liver and muscle 
caused by Ccl2 overexpression, indicating the active role of CCL2 in cell homeostasis. Indeed, targeting CCL2 
and other factors secreted by senescent cells alleviated metabolic dysfunction and showed efficacy in diabetes 
and  obesity33. In the present study, we observed different effects of CCL2 in the liver and muscle of mice. In the 
liver, Ccl2 overexpression resulted in steatosis, decreased AMPK activation, and upregulation of mTORC1. These 
alterations were associated with decreased oxidative phosphorylation and alterations in the citric acid cycle and 
transmethylation pathways. In contrast, in the muscle, we found increased AMPK activity and mTORC1 down-
regulation, together with an increase in oxidative phosphorylation processes and increased concentrations of 
β-hydroxybutyrate and lactate. Our data suggest a bidirectional interaction between CCL2 and mitochondrial 
function, which might explain the different changes in muscle and liver metabolism as a result of their distinct 
energy requirements. The effect of Ccl2 overexpression may be linked to alterations in mitochondrial dynam-
ics and the AMPK-driven pathways that regulate anabolic and catabolic  pathways34–36. In particular, CCL2 
appears to specifically affect the response in energy and one-carbon metabolism and autophagic processes with 
important repercussions on energy status. CgCcl2 mice showed an anabolic profile in the liver, decoupling of 
oxidative phosphorylation components and alterations in mitochondrial fusion, which have been previously 
related to liver  disease37,38. The response diverged in skeletal muscle, which had with a catabolic profile, increased 
expression of oxidative phosphorylation components and increased levels of lactate and ketone bodies without 
alterations in mitochondrial fusion markers. We found elevated levels of ATP in the livers of the CgCcl2 mice 
despite mitochondrial alterations and OXPHOS inhibition. This finding could be explained by the low expression 
of MFN2. Previous  studies39 reported that MFN2 loss-of-function causes a specific alteration in the expression 
of subunits that participate in complexes I, II, III and V, which leads to reduced activity of several components 
of the OXPHOS system. Under these conditions, MFN2 inhibition induces a higher rate of glucose uptake and 
glycolysis and a lower rate of glycogen synthesis, thus compensating for cell energy metabolism.
Metabolomic analysis showed that the CgCcl2 mice had different responses in the liver and muscle with 
respect to the accumulation of metabolites from one-carbon metabolism with likely metaboloepigenetic  effects40. 
The differences were also evident in the response of metabolites from the CAC that may induce mitochondrial 
dysfunction through G-protein-coupled receptor  signaling41. Some of these receptors may be blocked and have 
been assayed in the treatment of inflammatory conditions, but the associated metabolic events are contradic-
tory and diverse among the involved  tissues42,43. Our findings certainly illustrate the expected difficulties in the 
assessment of effects derived from the immune regulation of metabolic homeostasis and may partially explain 
the heterogeneous responses of AMPK stimulators among cells and  organs13,43.
In conclusion, Ccl2 gene overexpression can affect processes that are important for cell survival and homeo-
stasis, including mitochondrial dynamics and autophagy-related pathways. The differential response in tissues 
with different energetic needs may complicate the assessment of therapeutic strategies designed to block CCL2 
metabolic signaling.
Materials and methods
Animals and experimental design. We employed male Ccl2 cisgenic mice with a C57BL/6J genetic 
background that systemically overexpress Ccl2. These animals have an additional copy of the Ccl2 gene in the 
Gt(ROSA)26Sor locus in the mouse genome and were obtained via recombination in embryonic stem  cells13. 
The strain was backcrossed for > 10 generations to maintain homozygosity, and littermates without mutations 
were used as controls (WT). All mice were maintained in a facility with a controlled temperature (22 °C), humid-
ity (50%) and light/dark cycle (12/12 h). The mice were fed a normal standard diet from Scientific Animal Food 
and Engineering (SAFE, Augy, France) and water at libitum for 22 weeks. The animal procedures were designed 
according to European guidelines (Directive 2010/63/EU) and approved by the Ethics Review Committee for 
Animal Experimentation of Universitat Rovira i Virgili (protocols 4815 and GC-URV-0235-03.18.2014).
Sample collection and laboratory measurements. At sacrifice, blood was obtained by intracardiac 
puncture to measure serum glucose, cholesterol, and triglyceride concentrations and AST and ALT activities 
with a Roche Cobas Mira Plus automated analyzer (Roche Diagnostics, Basel, Switzerland). Portions of liver, 
epididymal white adipose tissue (eWAT), interscapular brown adipose tissue (BAT), pancreas and soleus/gas-
trocnemius skeletal muscle were frozen in liquid  N2 and stored at − 80 °C and/or fixed in formalin (3.7–4% 
formaldehyde buffered to pH 7 and stabilized with 1–1.5% methanol) until analysis. Thirty milligrams of the 
selected tissues was homogenized by using a sonicator (Branson Sonifer 150, Thistle Scientific, Glasgow, UK) in 
50 mM Tris with 1 mM EDTA, 1% Igepal CA-630, 150 mM NaCl, 0.10% Triton, 50 mM NaF, 100 mM phenyl-
methanesulfonyl fluoride and 1 mM  Na3VO4. To measure the CCL2 concentrations in liver, pancreas, muscle, 
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and white and brown adipose tissues by ELISAs (Preprotech, London UK), we used two hundred micrograms 
of protein from each tissue.
Histological analyses and immunohistochemistry. Two-micrometer-thick tissue sections were 
stained with hematoxylin and eosin and Sirius red to evaluate the histological alterations. For the immunohis-
tochemical analyses, we used 10 mM Tris, pH 6, with 1 mM EDTA for antigen retrieval in a microwave oven 
at 90 °C for 30 min. Bovine serum albumin (2%) was used to block nonspecific binding. Endogenous peroxi-
dases were blocked by hydrogen peroxide. Then, the sections were incubated with an antibody against F4/80 
(ab100790, Abcam, Cambridge, UK), which is a marker of macrophages, and a secondary antibody (P0448, 
Dako, Agilent, CA, USA). All sections were counterstained with Mayer’s hematoxylin.
Analysis of the morphology of mitochondria by transmission electron microscopy. Small 
pieces of the liver were immediately fixed in a 2% glutaraldehyde solution in 0.1 M cacodylate buffer, pH 7.4. 
The samples were then postfixed in 1% osmium tetroxide for 2 h and dehydrated in sequential steps of acetone 
prior to impregnation in increasing concentrations of the resin in acetone over a 24 h period. Semithin sec-
tions (500 nm) were stained with 1% toluidine blue. Ultrathin sections (70 nm) were subsequently cut using a 
diamond knife, double-stained with uranyl acetate and lead citrate, and examined using a transmission electron 
microscope (Hitachi, Tokyo, Japan). Mitochondrial density, elongation and interconnectivity were quantified 
using the method of Dagda et al.44.
Western blot analyses. Twenty milligrams of frozen liver and skeletal muscle tissues from each animal 
was homogenized by using a sonicator (Branson Sonifer 150). For hepatic tissue, we used 300 μL of lysis buffer 
composed of 0.25 M sucrose, 1 mM Pefabloc SC (Sigma-Aldrich, Saint Louis, MI, USA), and a phosphatase 
inhibitor cocktail (Hoffman-La Roche, Basel, Switzerland). For muscle tissue, we used 300 μL of lysis buffer 
composed of 50 mM Tris, 1 mM EDTA, 1% Igepal CA-630, 150 mM NaCl, 0.1% Triton, 50 mM NaF, 100 mM 
phenylmethanesulfonyl fluoride and 1 mM  Na3VO4. Western blotting was performed by denaturing 50 μg of 
protein at 100 °C for 5 min in Laemmli sample buffer and β-mercaptoethanol. For protein separation, an 8–14% 
sodium dodecyl sulfate–polyacrylamide gel was used, and the proteins were transferred onto a polyvinylidene 
difluoride or nitrocellulose membrane (Thermo Fisher, Barcelona, Spain). Before the primary antibody incuba-
tion, the membranes were blocked with 5% nonfat milk or bovine serum albumin in Tris, sodium chloride and 
1% Tween-20 (pH = 7.4). Other information on the reagents is shown in Supplementary Table S3. The bands 
were detected with SuperSignal West Femto chemiluminescent substrate (Pierce, Rockford, IL, USA), and the 
analysis was performed with a ChemiDoc system (Bio-Rad Laboratories, Madrid, Spain). The bands were ana-
lyzed and quantified using Image Lab 2.0 software (Bio-Rad Laboratories, Hercules, CA, USA). We explored 
the expression of proinflammatory and anti-inflammatory markers and molecules involved in the regulation 
of energy metabolism, autophagy and lysosomal  function14,45–48. Measurements were performed for CD11b, 
CD163, TNFα, phosphoinositide 3-kinase p85 subunit (PI3K-p85), AKT, phospho-AKT Ser 473 (AKT-pS473), 
S6, phospho-S6 ribosomal protein (S6-Ps235/236), TOM20, MFN2, AMPK, AMPK-pT172, PINK1, PARKIN, 
the oxidative phosphorylation complexes LC3I and LC3II, p62/SQSTM1 and LAMP2A. Fumarylacetoacetate 
hydrolase (FAH) and vinculin were used as reference proteins. Details on the source and handling of the anti-
bodies are described in Supplementary Table S3. The uncropped blots are shown in Supplementary Fig. S3.
ATP assay. ATP concentrations were analyzed by an ATP assay kit (ab83355, Abcam, Cambridge, UK) 
according to the manufacturer’s instructions. Briefly, 60 mg of liver and skeletal muscle was homogenized using 
a Dounce homogenizer in ATP assay buffer (Izasa, Barcelona, Spain). The homogenates were centrifuged at 
13,000g for 5 min at 4 °C and deproteinized with trichloroacetic acid (Deproteinizing Sample Preparation kit, 
ab204708, Cambridge, UK).
Quantitative real‑time polymerase chain reaction. Total RNA was extracted using an RNeasy kit 
(Qiagen, Barcelona, Spain) and was reversed transcribed using a Reverse Transcription System kit (Applied 
Biosystems; Invitrogen, Barcelona, Spain). Quantitative real-time PCR (qPCR) was conducted on a 7900HT Fast 
Real-Time PCR System using TaqMan Gene Expression Assays (Applied Biosystems). The results were normal-
ized according to the expression level of Beta-2-Microglobulin (B2M) mRNA.
Measurement of energy balance and one‑carbon metabolites in the liver and muscle tis‑
sue. The settings and conditions used for the instrumentation in the metabolomics analyses have been previ-
ously  described49,50. Briefly, for quantification of the metabolites involved in energy generation, 10 mg of liver 
and skeletal muscle was homogenized using a Precellys 24 homogenizer (Izasa, Barcelona, Spain) in 0.5 mL 
of methanol (MeOH)/H2O (8:2 v/v) containing  D4-succinic acid as an internal standard at a final concentra-
tion of 0.01 μM. The samples were stored at − 20 °C for 2 h to precipitate the proteins and then centrifuged at 
15,000 rpm for 10 min at 4 °C. The supernatants were collected, dried under  N2 flow and derivatized with meth-
oxyamine hydrochloride dissolved in pyridine (40 mg/ml) and N-methyl-N-trimethylsilyl trifluoroacetamide. 
The analyses were performed with a 7890A gas chromatograph coupled via an electron impact source to a 7,200 
quadrupole time-of-flight mass spectrometer (GC-EI-QTOF-MS) equipped with a J&W Scientific HP-5MS col-
umn (30 m × 0.25 mm, 0.25 μm) (Agilent Technologies, Santa Clara, CA, USA).
For quantification of the intermediaries involved in one-carbon metabolism, 0.5 mL of MeOH:H2O (8:2 
v/v) containing 1% ascorbic acid (m/v) and 0.5% β-mercaptoethanol (v/v) was added to 10 mg of liver and 
10
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:11954  | https://doi.org/10.1038/s41598-020-68769-7
www.nature.com/scientificreports/
skeletal muscle and homogenized. After protein precipitation for 2 h at − 20 °C, the samples were centrifuged 
at 15,000 rpm at 4 °C for 10 min, the supernatant was collected, and the homogenization step was repeated. 
Nonpolar metabolites were removed by adding 2 mL of chloroform/methanol (2:1, v/v) to prevent interference 
in the analysis. After 10 min of agitation, the samples were centrifuged at 15,000 rpm for 10 min at 4 °C, and 
the polar phase was collected, dried under  N2 flow and stored at − 80 °C until analysis. The samples were then 
resuspended in 100 µL of ultrapure type 1 water containing 50 mM ammonium acetate plus 0.2% formic acid 
and placed into chromatographic vials for analysis by a 1,290 Infinity ultra-high-performance liquid chroma-
tography instrument coupled to a 6,490 triple quadrupole-mass spectrometer using an electrospray ionization 
source (Agilent Technologies) and equipped with an Acquity UPLC HSS T3 column (2.1 × 150 mm, 1.8 μm) 
(Waters Corporation, Milford, MA, USA).
Statistical analyses. The statistical analyses were performed using nonparametric Mann–Whitney U-tests 
with IBM SPSS Statistics for Windows, Version 21 (Armonk, NY, USA, IBM Corp.). Selected metabolites 
were quantitated across all the samples using MassHunter Quantitative Analysis B.07.00 (Agilent Technolo-
gies) according to the calibration curve of its corresponding standard. The PLS-DA analysis and the variable 
importance in projection (VIP) score were calculated with MetaboAnalyst 4.0 (https ://www.metab oanal yst.ca) 
 software51. Differences were considered statistically significant when the P value was ≤ 0.05. Unless otherwise 
indicated, the results are expressed as the mean ± standard error of the mean.
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